Personalis Pre-Paid Expenses 2018-2024 | PSNL

Personalis pre-paid expenses from 2018 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
Personalis Annual Pre-Paid Expenses
(Millions of US $)
2023 $4
2022 $7
2021 $7
2020 $5
2019 $3
2018 $2
2017 $
Personalis Quarterly Pre-Paid Expenses
(Millions of US $)
2024-06-30 $4
2024-03-31 $5
2023-12-31 $4
2023-09-30 $6
2023-06-30 $5
2023-03-31 $8
2022-12-31 $7
2022-09-30 $8
2022-06-30 $6
2022-03-31 $6
2021-12-31 $7
2021-09-30 $8
2021-06-30 $9
2021-03-31 $6
2020-12-31 $5
2020-09-30 $5
2020-06-30 $3
2020-03-31 $3
2019-12-31 $3
2019-09-30 $4
2019-06-30 $2
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.278B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Supernus Pharmaceuticals (SUPN) United States $2.089B 28.44
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00